Safety Considerations for New Therapies

Opinion
Video

Experts discuss the safety of aflibercept 8 mg, emphasizing familiarity, efficacy, and durability, supported by reassuring data from the two-year PULSAR and PHOTON studies.

Summary

In this segment, the discussion focuses on the safety considerations of aflibercept 8 mg, particularly in relation to intraocular inflammation (IOI) and retinal vasculitis. David Eichenbaum, MD asks Kenny Fan, MD, MBA about his concerns regarding safety considering the higher dose of aflibercept. Fan expresses confidence in the safety profile of aflibercept 8 mg, highlighting the advantage of switching patients to a drug they are already familiar with, while providing the opportunity of higher efficacy and durability. He mentions the reassuring safety data from the two-year PULSAR and PHOTON studies, emphasizing the absence of significant safety concerns such as IOI and increased intraocular pressure (IOP). Experts discuss label modifications for both aflibercept and faricimab related to the rare occurrence of retinal vasculitis. Diana Do, MD responds, acknowledging the label modification but underscores that the chance of retinal vasculitis is extremely low and rare. She emphasizes the overall excellent safety profile observed in the data, providing increased confidence in discussing safety issues with patients. The conversation highlights the importance of considering safety aspects when discussing treatment options with patients and how the latest data can influence the narrative around potential risks.

This summary was AI-generated and edited for clarity.

Related Videos
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.